d.c.

Court Ruling Pressures Stem Cell Stocks

Following Monday's ruling in the Federal District Court for Washington, D.C., to block federal funding for research that uses human embryonic stem cells, companies researching and developing medical techniques involving stem cells saw shares tumble down today across the board.